How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about ruxolitinib

Marketing authorisation indication

2.1

Ruxolitinib (Jakavi, Novartis) is indicated for 'the treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids'.

Dosage in the marketing authorisation

Price

2.3

The list price for a 56-tablet pack of 5 mg ruxolitinib is £1,428, and for a 56-tablet pack of 10 mg ruxolitinib is £2,856 (excluding VAT; BNF online, accessed November 2024).

2.4

The company has a commercial arrangement. This makes ruxolitinib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence.